Astrazeneca (AZN) Receivables - Other (2016 - 2026)

Astrazeneca has reported Receivables - Other over the past 15 years, most recently at $1.2 billion for Q1 2026.

For Q1 2026, Receivables - Other rose 28.08% year-over-year to $1.2 billion; the TTM value through Mar 2026 reached $1.2 billion, up 28.08%, while the annual FY2025 figure was $2.0 billion, 27.74% up from the prior year.
Receivables - Other for Q1 2026 was $1.2 billion at Astrazeneca, down from $1.3 billion in the prior quarter.
Over five years, Receivables - Other peaked at $1.7 billion in Q4 2022 and troughed at $682.0 million in Q1 2023.
A 5-year average of $1.0 billion and a median of $915.0 million in 2024 define the central range for Receivables - Other.
Biggest five-year swings in Receivables - Other: surged 99.19% in 2022 and later fell 21.06% in 2023.
Year by year, Receivables - Other stood at $1.7 billion in 2022, then dropped by 1.21% to $1.6 billion in 2023, then fell by 3.66% to $1.6 billion in 2024, then fell by 15.96% to $1.3 billion in 2025, then decreased by 10.63% to $1.2 billion in 2026.
Business Quant data shows Receivables - Other for AZN at $1.2 billion in Q1 2026, $1.3 billion in Q4 2025, and $1.2 billion in Q3 2025.

Peer Comparison